NEW YORK (GenomeWeb News) – XDx today announced a deal with Laboratory Corporation of America to develop and commercialize a diagnostic test for systemic lupus erythematosus (SLE).

The two firms will work together in the discovery phase while LabCorp will develop and commercialize a test to predict flares of lupus. The collaboration pairs XDx's autoimmune diagnostics research and discovery expertise as well as SLE blood sample database with LabCorp's diagnostic development and commercialization resources, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.